• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation.

作者信息

Justet Aurélien, Thabut Gabriel, Manali Effrosyni, Molina Molina Maria, Kannengiesser Caroline, Cadranel Jacques, Cottin Vincent, Gondouin Anne, Nunes Hilario, Magois Eline, Tromeur Cécile, Prevot Grégoire, Papiris Spyros, Marchand-Adam Sylvain, Gamez Anne Sophie, Reynaud-Gaubert Martine, Wemeau Lidwine, Crestani Bruno, Borie Raphael

机构信息

APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France.

INSERM, Unité 1152, Université Paris Diderot, Paris, France.

出版信息

Eur Respir J. 2018 Mar 15;51(3). doi: 10.1183/13993003.01875-2017. Print 2018 Mar.

DOI:10.1183/13993003.01875-2017
PMID:29449422
Abstract
摘要

相似文献

1
Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation.吡非尼酮在携带端粒酶复合体突变患者中的安全性和有效性。
Eur Respir J. 2018 Mar 15;51(3). doi: 10.1183/13993003.01875-2017. Print 2018 Mar.
2
Photoallergic contact dermatitis due to treatment of pulmonary fibrosis with pirfenidone.吡非尼酮治疗肺纤维化引起的光变应性接触性皮炎。
J Eur Acad Dermatol Venereol. 2016 Feb;30(2):370-1. doi: 10.1111/jdv.12794. Epub 2014 Oct 20.
3
Pirfenidone-induced Eosinophilic Pleurisy.吡非尼酮诱发的嗜酸性粒细胞性胸膜炎。
Intern Med. 2017;56(14):1863-1866. doi: 10.2169/internalmedicine.56.7738. Epub 2017 Jul 15.
4
Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis.与吡非尼酮用于特发性肺纤维化相关的严重结肠炎。
Ann Am Thorac Soc. 2016 Aug;13(8):1430-2. doi: 10.1513/AnnalsATS.201602-118LE.
5
Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.吡非尼酮治疗严重特发性肺纤维化的安全性和有效性：一项真实世界的观察性研究。
Pulm Pharmacol Ther. 2017 Oct;46:48-53. doi: 10.1016/j.pupt.2017.08.011. Epub 2017 Aug 24.
6
Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.特发性肺纤维化患者对吡非尼酮治疗的个体内反应。
Am J Respir Crit Care Med. 2015 Jan 1;191(1):110-3. doi: 10.1164/rccm.201406-1106LE.
7
Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation.吡非尼酮用于治疗特发性肺纤维化：治疗潜力促使进一步研究。
Expert Opin Investig Drugs. 2005 Nov;14(11):1443-7. doi: 10.1517/13543784.14.11.1443.
8
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化患者的双盲、安慰剂对照试验。
Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7. doi: 10.1164/rccm.200404-571OC. Epub 2005 Jan 21.
9
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.对慢性肺纤维化患者进行为期一年的吡非尼酮开放标签同情用药治疗。
Intern Med. 2002 Dec;41(12):1118-23. doi: 10.2169/internalmedicine.41.1118.
10
Reactivation pulmonary tuberculosis in two patients treated with pirfenidone.两名接受吡非尼酮治疗的患者发生了复发性肺结核。
Int J Mycobacteriol. 2017 Apr-Jun;6(2):193-195. doi: 10.4103/ijmy.ijmy_64_17.

引用本文的文献

1
Telomeropathies in Interstitial Lung Disease and Lung Transplant Recipients.间质性肺疾病和肺移植受者中的端粒病
J Clin Med. 2025 Feb 24;14(5):1496. doi: 10.3390/jcm14051496.
2
Walking the path of treatable traits in interstitial lung diseases.在间质性肺疾病中探寻可治疗的特征。
Respir Res. 2023 Oct 24;24(1):251. doi: 10.1186/s12931-023-02554-8.
3
Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective.特发性肺纤维化中的遗传学：临床视角
Diagnostics (Basel). 2022 Nov 23;12(12):2928. doi: 10.3390/diagnostics12122928.
4
Compound heterozygous mutation of RTEL1 in interstitial lung disease complicated with pneumothorax and emphysema: A case report and literature review.间质肺疾病合并气胸和肺气肿中RTEL1的复合杂合突变：一例报告及文献综述
Respirol Case Rep. 2022 Sep 6;10(10):e01032. doi: 10.1002/rcr2.1032. eCollection 2022 Oct.
5
Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis.特发性肺纤维化的分子机制、治疗靶点及药物研发研究进展
Front Pharmacol. 2022 Jul 21;13:963054. doi: 10.3389/fphar.2022.963054. eCollection 2022.
6
The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis.端粒与表面活性剂相关的家族性肺纤维化患者肺部炎症细胞浸润和纤维化的程度
Front Med (Lausanne). 2021 Sep 24;8:736485. doi: 10.3389/fmed.2021.736485. eCollection 2021.
7
Pulmonary fibrosis in dyskeratosis congenita: a case report with a PRISMA-compliant systematic review.先天性角化不良症中的肺纤维化：一例病例报告及 PRISMA 合规性系统评价。
BMC Pulm Med. 2021 Sep 3;21(1):279. doi: 10.1186/s12890-021-01645-w.
8
Dyspnoea with progressive "idiopathic" pulmonary fibrosis.进行性“特发性”肺纤维化伴呼吸困难
Respirol Case Rep. 2021 Jun 6;9(7):e00800. doi: 10.1002/rcr2.800. eCollection 2021 Jul.
9
Telomeres in Interstitial Lung Disease.间质性肺疾病中的端粒
J Clin Med. 2021 Mar 30;10(7):1384. doi: 10.3390/jcm10071384.
10
Early Career Members at the ERS Lung Science Conference 2020: metabolic alterations in lung ageing and disease.2020年欧洲呼吸学会肺部科学会议的青年成员：肺部衰老和疾病中的代谢改变
Breathe (Sheff). 2020 Sep;16(3):200063. doi: 10.1183/20734735.0063-2020.